Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 311 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Overweight Subjects Clear all

Conditions: Obstructive Sleep Apnea, Sleep Apnea, Sleep-disordered Breathing
Interventions: Positive Pressure Therapy (PAP), LifeStyle Counseling; Device · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Disorders, Non-alcoholic Steatohepatitis
Interventions: AZD2693, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Obesity, Overweight
Interventions: NNC0174-0833, Semaglutide, Placebo (NNC0174-0833); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Resting Metabolic Rate, Overweight Subjects
Interventions: 7-Keto 50mg, 7-Keto 25mg, Placebo; Dietary Supplement
Lead sponsor: KGK Science Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Foothill Ranch, California • Orlando, Florida

Conditions: Obesity
Interventions: LAP-BAND System; Device
Lead sponsor: Apollo Endosurgery, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Weight Loss
Interventions: Resting Metabolic Rate (RMR), Duel-energy x-ray absorptiometry (DEXA), Visual Analog Scale (VAS), Meal Stimulation Test; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Nicotine Dependence, Overweight, Obesity
Interventions: NB32, Ancillary therapy; Drug · Behavioral
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Encino, California • Los Alamitos, California • Newport Beach, California

Conditions: Overweight, Obesity
Interventions: pramlintide acetate, sibutramine, phentermine, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more

Conditions: Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions: DELPhI system; Device
Lead sponsor: QuantalX Neuroscience; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio

Conditions: Obesity
Interventions: pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 21
States / cities: Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more

Conditions: Non-Alcoholic Steatohepatitis
Interventions: SHP626, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Obesity and Diabetes Mellitus, Type 2
Interventions: JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Rancho Cucamonga, California + 20 more

Conditions: Healthy
Interventions: P7435, Placebo; Drug · Other
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 2 Diabetes
Interventions: 18F-AV-133, 10% Arginine Hydrochloride-R-Gene 10; Drug
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity
Interventions: Placebo, Pramlintide and Metreleptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arkansas • Santa Rosa, California + 30 more

Conditions: Obesity and Overweight
Interventions: NNC0165-1875, Placebo (NNC0165-1875), Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bariatric Surgery, Obesity, Weight Gain
Interventions: ARD-101; Drug
Lead sponsor: Aardvark Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Obesity, Frailty, Elderly
Interventions: diet, exercise; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Obesity
Interventions: S-2367 (velneperit); Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 73
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more

Conditions: Obesity
Interventions: Semaglutide Injectable Product (not provided by the study); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Obesity, Overweight
Interventions: AC2307, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Chandler, Arizona • Santa Rosa, California + 15 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 12
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more

Conditions: Overweight, Obesity
Interventions: VI-0521, Placebo, Alcohol, alcohol placebo; Drug · Other
Lead sponsor: VIVUS LLC; Industry
Eligibility: 21 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity
Interventions: RS2 (RESTORe Suturing System); Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Boston, Massachusetts • Cleveland, Ohio

Search by objective public record fields.

Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism

A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults

Effectiveness and Safety Study of LAP-BAND Treatment in Subjects With BMI >/= 30 kg/m2 and < 40 kg/m2

Changes in Gut Hormones, Body Composition and Energy Expenditure After Roux-en-Y

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

DELPHI in Subjects at Risk for Stroke and Dementia

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery

Weight Loss and Exercise in Physically Limited Obese Elderly Subjects

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

A Study to Evaluate How VI-0521 Affect Psychomotor Performance in Healthy Overweight and Obese Subjects.

Transoral Gastric Volume Reduction as an Intervention for Weight Management